Miller Fisher syndrome
disease diseaseOn this page
Also known as cranial variant of GBScranial variant of Guillain-Barre syndromecranial variant of Guillain-Barré syndromeFisher syndromeGuillain Barre syndrome, Miller Fisher variantGuillain-Barre syndrome, Miller Fisher variantMiller Fisher variant of Guillain Barre syndromeMiller-Fisher syndromeophthalmoplegia, ataxia and areflexia syndromesyndrome, Fishersyndrome, Miller Fishersyndrome, Miller-Fisher
Summary
Miller Fisher syndrome (MONDO:0005851) is a disease and 2 clinical trials. Top therapeutic interventions include fibrinogen, human. A subtype of autoimmune disorder of central nervous system — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 26
- Clinical trials: 2
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.1 | Europe | Validated |
| Point prevalence | 1-9 / 1 000 000 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
26 HPO clinical features (Orphanet curated; top 26 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000544 | External ophthalmoplegia | Very frequent (80-99%) |
| HP:0001284 | Areflexia | Very frequent (80-99%) |
| HP:0034122 | Anti-GQ1b antibody positivity | Very frequent (80-99%) |
| HP:0000651 | Diplopia | Frequent (30-79%) |
| HP:0000666 | Horizontal nystagmus | Frequent (30-79%) |
| HP:0001251 | Ataxia | Frequent (30-79%) |
| HP:0002922 | Increased CSF protein concentration | Frequent (30-79%) |
| HP:0003457 | EMG abnormality | Frequent (30-79%) |
| HP:0007942 | Internal ophthalmoplegia | Frequent (30-79%) |
| HP:0010845 | EEG with generalized slow activity | Frequent (30-79%) |
| HP:0011499 | Mydriasis | Frequent (30-79%) |
| HP:0000613 | Photophobia | Occasional (5-29%) |
| HP:0000622 | Blurred vision | Occasional (5-29%) |
| HP:0001283 | Bulbar palsy | Occasional (5-29%) |
| HP:0001945 | Fever | Occasional (5-29%) |
| HP:0002273 | Tetraparesis | Occasional (5-29%) |
| HP:0002315 | Headache | Occasional (5-29%) |
| HP:0003401 | Paresthesia | Occasional (5-29%) |
| HP:0004372 | Reduced consciousness/confusion | Occasional (5-29%) |
| HP:0009916 | Anisocoria | Occasional (5-29%) |
| HP:0010628 | Facial palsy | Occasional (5-29%) |
| HP:0011347 | Abnormality of ocular abduction | Occasional (5-29%) |
| HP:0012229 | CSF pleocytosis | Occasional (5-29%) |
| HP:0000508 | Ptosis | Very rare (<1-4%) |
| HP:0002013 | Vomiting | Very rare (<1-4%) |
| HP:0002015 | Dysphagia | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Miller Fisher syndrome |
| Mondo ID | MONDO:0005851 |
| EFO | EFO:0007371 |
| MeSH | D019846 |
| Orphanet | 98919 |
| DOID | DOID:12889 |
| ICD-11 | 134795253 |
| NCIT | C116958 |
| SNOMED CT | 1767005 |
| UMLS | C0393799 |
| MedGen | 95994 |
| GARD | 0003668 |
| MedDRA | 10049567 |
| Is cancer (heuristic) | no |
Also known as: cranial variant of GBS · cranial variant of Guillain-Barre syndrome · cranial variant of Guillain-Barré syndrome · Fisher syndrome · Guillain Barre syndrome, Miller Fisher variant · Guillain-Barre syndrome, Miller Fisher variant · Miller Fisher variant of Guillain Barre syndrome · Miller-Fisher syndrome · ophthalmoplegia, ataxia and areflexia syndrome · syndrome, Fisher · syndrome, Miller Fisher · syndrome, Miller-Fisher
Disease family
This is a subtype of autoimmune disorder of central nervous system. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autoimmune disorder of central nervous system › Miller Fisher syndrome
Related subtypes (7): multiple sclerosis, autoimmune encephalopathy with parasomnia and obstructive sleep apnea, lymphocytic hypophysitis, autoimmune encephalitis, autoimmune optic neuritis, central nervous system lupus, autoimmune epilepsy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01582763 | Not specified | COMPLETED | International Guillain-Barré Syndrome Outcome Study |
| NCT03801135 | Not specified | UNKNOWN | Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FIBRINOGEN, HUMAN | 3 | 1 |
Related Atlas pages
- Drugs: Fibrinogen, Human